1025720-94-8 Usage
Description
N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is a complex organic compound with a unique chemical structure. It is characterized by its fluorophenyl and pyridine moieties, which contribute to its biological activity and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is used as a selective and orally efficacious inhibitor of the Met Kinase superfamily for the treatment of various diseases. Its application in this industry is due to its ability to selectively target and inhibit the Met Kinase superfamily, which plays a crucial role in cell growth, proliferation, and survival, and is often dysregulated in various diseases, including cancer.
Used in Cancer Research:
In the field of cancer research, N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is used as a potential therapeutic agent for the treatment of cancer. Its application in this field is based on its ability to inhibit the Met Kinase superfamily, which is often overactivated in various types of cancer, leading to uncontrolled cell growth and tumor progression.
Used in Drug Development:
N-[4-[(2-Amino-3-chloropyridin-4-yl)oxy]-3-fluorophenyl]-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide is also used in drug development as a lead compound for the design and synthesis of novel inhibitors targeting the Met Kinase superfamily. Its application in this field is due to its structural features and biological activity, which make it a promising starting point for the development of new drugs with improved potency, selectivity, and pharmacokinetic properties.
Biological Activity
bms 777607 is a novel, selective and orally available atp-competitive met kinase inhibitor that primarily targets several met family members, including ron, met, tyro-3 and axi, with half maximal inhibitory concentration ic50 of 1.8 nmol/l, 3.9 nmol/l, 4.3 nmol/l and 1.1 nmol/l respectively. moreover, at higher concentrations, bms 777607 has been found to inhibit other protein tyrosine kinases, including mer, flt-3, aurora b, lck and vegfr2 with ic50 of 14 nmol/l, 16 nmol/l, 78 nmol/l, 120 nmol/l and 180 nmol/l respectively. in previous studies, bms 777607 potently inhibited the auto-phosphorylation of c-met (ic50: 20 nmol/l) leading to impaired xenograft growth.small-molecule inhibitor bms-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. mol cancer ther. 2013 may;12(5):725-36. doi: 10.1158/1535-7163.mct-12-1079. epub 2013 mar 6.
references
[1]dai y, siemann dw. bms-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. mol cancer ther. 2010 jun;9(6):1554-61. doi: 10.1158/1535-7163.mct-10-0359. epub 2010 jun 1.[2]sharma s, zeng jy, zhuang cm, zhou yq, yao hp, hu x, zhang r, wang mh.
Check Digit Verification of cas no
The CAS Registry Mumber 1025720-94-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,5,7,2 and 0 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1025720-94:
(9*1)+(8*0)+(7*2)+(6*5)+(5*7)+(4*2)+(3*0)+(2*9)+(1*4)=118
118 % 10 = 8
So 1025720-94-8 is a valid CAS Registry Number.
1025720-94-8Relevant articles and documents
PHOSPHONATE CONJUGATES AND USES THEREOF
-
, (2020/07/31)
Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.
PYRIDINONE COMPOUNDS
-
Page/Page column 9, (2008/12/05)
The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: and is further directed to pharmaceutical compositions comprising the compound; and methods for treating proliferative diseases, such as ca